Recent Updates
Recently added Catalysts
BIOA Negative Sentiment Score: 25/100

BIOAGE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioAge Labs, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been filed against BioAge Labs, Inc. following the company's decision to discontinue the STRIDES Phase 2 trial for its lead product candidate, azelaprag, due to safety concerns. This announcement, made on December 6, 2024, resulted in a significant decline in BioAge's stock price from $20.09 to $4.65. Investors are encouraged to contact the law firm Bragar Eagel & Squire for more information regarding their participation in the lawsuit, which affects those who purchased shares during the company's recent IPO.

Market Sentiment Analysis

CONCERNS & RISKS

  • BioAge discontinued its STRIDES Phase 2 trial for azelaprag due to safety concerns.
  • The stock price fell significantly from $20.09 to $4.65 within a day.
  • A class action lawsuit has been filed against BioAge Labs, potentially leading to further financial and reputational damage.

Full Press Release Details

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired BioAge securities pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024 (the “Class Period”). Investors have until March 10, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs.
Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
If you purchased or otherwise acquired BioAge shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What lawsuit was filed against BioAge Labs?

A class action lawsuit was filed against BioAge Labs in January 2025 for misleading investors during its IPO.

What caused BioAge's stock price to decline?

BioAge’s stock dropped after the announcement of discontinuing the STRIDES Phase 2 trial due to safety concerns.

What are the dates for filing claims in the lawsuit?

Investors must apply by March 10, 2025, to be appointed as lead plaintiff.

Who can participate in the class action lawsuit?

Individuals or entities that purchased BioAge securities during the Class Period can participate.

How can investors contact Bragar Eagel & Squire?

Investors can reach out via email at investigations@bespc.com or call (212) 355-4648.

Last updated: Jan 8, 2025